先聲藥業(02096.HK)小分子抑制劑新藥臨床試驗申請獲美FDA批准

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)小分子抑制劑新藥臨床試驗申請獲美FDA批准

阿思達克 12-05 01:01

先聲藥業(02096.HK)公布，集團自主研發的抗腫瘤候選藥物－泛素特異性(月太)(酉每)1「USP1」小分子抑制劑SIM0501新藥臨床試驗申請獲美國食品藥品監督管理(FDA)局准，擬開展用於晚期實體瘤的臨床試驗。此外，SIM0501新藥臨床試驗申請已於10月27日獲中國國家藥品監督管理局受理。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)小分子抑制劑新藥臨床試驗申請獲美FDA批准

Services

About Us

Agreement Statement